These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 11813933)

  • 1. Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2-selective inhibitors: analysis of a large United States claims database.
    Schnitzer TJ; Kong SX; Mavros PP; Straus WL; Watson DJ
    Clin Ther; 2001 Dec; 23(12):1984-98. PubMed ID: 11813933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Underutilization of preventive strategies in patients receiving NSAIDs.
    Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of prophylactic gastroprotective therapy in patients with nonsteroidal anti-inflammatory drug- and aspirin-associated ulcer bleeding: a cross-sectional study.
    Ho CW; Tse YK; Wu B; Mulder CJ; Chan FK
    Aliment Pharmacol Ther; 2013 Apr; 37(8):819-24. PubMed ID: 23432193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-prescription of gastroprotective agents in patients taking non-selective NSAIDs or COX-2 selective inhibitors: analysis of prescriptions.
    Pasina L; Nobili A; Tettamanti M; Riva E; Lucca U; Piccinelli R; Defendi L; Perego L; Lucifora S; Bulla C
    Int J Clin Pharmacol Ther; 2010 Nov; 48(11):735-43. PubMed ID: 20979932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescription of and adherence to non-steroidal anti-inflammatory drugs and gastroprotective agents in at-risk gastrointestinal patients.
    Lanas A; Polo-Tomás M; Roncales P; Gonzalez MA; Zapardiel J
    Am J Gastroenterol; 2012 May; 107(5):707-14. PubMed ID: 22334248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rate of prescribing gastrointestinal prophylaxis with either a proton pump inhibitor or an H2-receptor antagonist in Nova Scotia seniors starting nonsteroidal anti-inflammatory drug therapy.
    Superceanu B; Veldhuyzen van Zanten S; Skedgel C; Shepherd M; Sketris I
    Can J Gastroenterol; 2010 Aug; 24(8):481-8. PubMed ID: 20711527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiation of antihypertensive therapy among new users of cyclooxygenase-2-selective and nonselective NSAIDs.
    Langman MJ; Eichler HG; Mavros P; Watson DJ; Kong SX
    Int J Clin Pharmacol Ther; 2004 May; 42(5):260-6. PubMed ID: 15176648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile.
    Arellano FM; Yood MU; Wentworth CE; Oliveria SA; Rivero E; Verma A; Rothman KJ
    Pharmacoepidemiol Drug Saf; 2006 Dec; 15(12):861-72. PubMed ID: 17086563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant use of gastroprotective drugs among elderly NSAID/COX-2 selective inhibitor users: a nationwide register-based study.
    Johnell K; Fastbom J
    Clin Drug Investig; 2008; 28(11):687-95. PubMed ID: 18840011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrointestinal-related healthcare resource usage associated with a fixed combination of diclofenac and misoprostol versus other NSAIDs.
    Rahme E; Joseph L; Kong SX; Watson DJ; Pellissier JM; LeLorier J
    Pharmacoeconomics; 2001; 19(5 Pt 2):577-88. PubMed ID: 11465302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescription of nonsteroidal anti-inflammatory drugs for elderly people in Alberta.
    Hogan DB; Campbell NR; Crutcher R; Jennett P; MacLeod N
    CMAJ; 1994 Aug; 151(3):315-22. PubMed ID: 8039085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risk of upper gastrointestinal bleeding in elderly users of aspirin and other non-steroidal anti-inflammatory drugs: the role of gastroprotective drugs.
    Pilotto A; Franceschi M; Leandro G; Paris F; Niro V; Longo MG; D'Ambrosio LP; Andriulli A; Di Mario F
    Aging Clin Exp Res; 2003 Dec; 15(6):494-9. PubMed ID: 14959953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis.
    Burke TA; Zabinski RA; Pettitt D; Maniadakis N; Maurath CJ; Goldstein JL
    Pharmacoeconomics; 2001; 19 Suppl 1():33-47. PubMed ID: 11280104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonsteroidal antiinflammatory drug use among patients with GI bleeding.
    Dominick KL; Bosworth HB; Jeffreys AS; Grambow SC; Oddone EZ; Horner RD
    Ann Pharmacother; 2004; 38(7-8):1159-64. PubMed ID: 15187205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastro-duodenal protection in an era of cyclo-oxygenase-2-selective nonsteroidal anti-inflammatory drugs.
    Naesdal J; Wilson I
    Eur J Gastroenterol Hepatol; 2001 Dec; 13(12):1401-6. PubMed ID: 11742186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescription audit of NSAIDs and gastroprotective strategy in elderly in primary care.
    Al Khaja KAJ; Veeramuthu S; Isa HA; Sequeira RP
    Int J Risk Saf Med; 2017; 29(1-2):57-68. PubMed ID: 28885223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Underutilization of gastrointestinal prophylaxis in high-risk chronic nonsteroidal anti-inflammatory drug users in Korea.
    Kim WY; Lee S; Jun K; Ah YM; Lee JY
    Int J Clin Pharm; 2021 Jun; 43(3):645-653. PubMed ID: 33147346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications.
    Goldstein JL; Howard KB; Walton SM; McLaughlin TP; Kruzikas DT
    Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1337-45. PubMed ID: 17088110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diclofenac/misoprostol. A review of its pharmacology and therapeutic efficacy in painful inflammatory conditions.
    Davis R; Yarker YE; Goa KL
    Drugs Aging; 1995 Nov; 7(5):372-93. PubMed ID: 8573992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of gastroprotective agent (GPA) use in adults with arthritis in the United States.
    Coyne KS; Margolis MK; Cappelleri JC; Hsieh R; Essex MN; Park PW; Joshi AV
    Curr Med Res Opin; 2013 May; 29(5):421-33. PubMed ID: 23444970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.